https://www.timesofisrael.com/new-israeli-drug-cured-moderate-to-serious-covid-cases-within-days-hospital/?fbclid=IwAR1xDSMlcVTJnpQb4pbZ263dP9Y83XJ7Uc9khWGA0Sqj-04-zJCNflNPlhY
Medicine developed at Ichilov moderates immune response, helps prevent deadly cytokine storm, researchers say; 29 of 30 phase 1
trial patients left hospital within 3-5 days. All 30 patients recovered.
It uses exosomes — tiny carrier sacs that shuttle materials between cells — to deliver a protein called CD24 to the lungs, which
Arber has spent decades researching.
https://www.cancer.gov/news-events/cancer-currents-blog/2019/cd24-immunotherapy-target
Medicine developed at Ichilov moderates immune response, helps prevent deadly cytokine storm, researchers say; 29 of 30 phase 1
trial patients left hospital within 3-5 days. All 30 patients recovered.
It uses exosomes — tiny carrier sacs that shuttle materials between cells — to deliver a protein called CD24 to the lungs, which
Arber has spent decades researching.
https://www.cancer.gov/news-events/cancer-currents-blog/2019/cd24-immunotherapy-target
https://www.timesofisrael.com/new-israeli-drug-cured-moderate-to-serious-covid-cases-within-days-hospital/?fbclid=IwAR1xDSMlcVTJnpQb4pbZ263dP9Y83XJ7Uc9khWGA0Sqj-04-zJCNflNPlhY
Medicine developed at Ichilov moderates immune response, helps prevent deadly cytokine storm, researchers say; 29 of 30 phase 1
trial patients left hospital within 3-5 days. All 30 patients recovered.
It uses exosomes — tiny carrier sacs that shuttle materials between cells — to deliver a protein called CD24 to the lungs, which
Arber has spent decades researching.
https://www.cancer.gov/news-events/cancer-currents-blog/2019/cd24-immunotherapy-target
0 Comments
0 Shares
328 Views
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek